HRP20200161T1 - (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja - Google Patents

(r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja Download PDF

Info

Publication number
HRP20200161T1
HRP20200161T1 HRP20200161TT HRP20200161T HRP20200161T1 HR P20200161 T1 HRP20200161 T1 HR P20200161T1 HR P20200161T T HRP20200161T T HR P20200161TT HR P20200161 T HRP20200161 T HR P20200161T HR P20200161 T1 HRP20200161 T1 HR P20200161T1
Authority
HR
Croatia
Prior art keywords
treatment
pharmaceutically acceptable
compound
methylbenzyl
piperidin
Prior art date
Application number
HRP20200161TT
Other languages
English (en)
Croatian (hr)
Inventor
Lorin A. Thompson
John E. Macor
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20200161T1 publication Critical patent/HRP20200161T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20200161TT 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja HRP20200161T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925405P 2014-01-09 2014-01-09
EP15702312.8A EP3092223B1 (en) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
PCT/US2015/010552 WO2015105929A1 (en) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Publications (1)

Publication Number Publication Date
HRP20200161T1 true HRP20200161T1 (hr) 2020-05-01

Family

ID=52444626

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200161TT HRP20200161T1 (hr) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja

Country Status (27)

Country Link
US (10) US9187506B2 (enExample)
EP (2) EP3677578A1 (enExample)
JP (1) JP6629738B2 (enExample)
KR (1) KR102331120B1 (enExample)
AR (1) AR102019A1 (enExample)
AU (1) AU2015204785A1 (enExample)
CA (1) CA2936338A1 (enExample)
CL (1) CL2016001744A1 (enExample)
CY (1) CY1122768T1 (enExample)
DK (1) DK3092223T3 (enExample)
EA (1) EA201691133A1 (enExample)
ES (1) ES2771825T3 (enExample)
HR (1) HRP20200161T1 (enExample)
HU (1) HUE048750T2 (enExample)
IL (1) IL246596A0 (enExample)
LT (1) LT3092223T (enExample)
MX (1) MX2016008715A (enExample)
PE (1) PE20160898A1 (enExample)
PL (1) PL3092223T3 (enExample)
PT (1) PT3092223T (enExample)
RS (1) RS59858B1 (enExample)
SG (1) SG11201605620QA (enExample)
SI (1) SI3092223T1 (enExample)
SM (1) SMT202000094T1 (enExample)
TW (1) TW201612169A (enExample)
UY (1) UY35946A (enExample)
WO (1) WO2015105929A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2018004256A (es) 2015-10-14 2018-05-16 Squibb Bristol Myers Co Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CA3001894A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks
WO2024197289A1 (en) * 2023-03-22 2024-09-26 Gilgamesh Pharmaceuticals, Inc. Negative allosteric modulators of glun2b receptors and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
MXPA02009659A (es) 2000-04-26 2003-03-10 Warner Lambert Co Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda.
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
KR20060017839A (ko) 2003-06-04 2006-02-27 머크 앤드 캄파니 인코포레이티드 Ｎｍｄａ／ｎｒ2ｂ 길항제로서 3-플루오로-피페리딘
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
CN102036985A (zh) * 2007-11-13 2011-04-27 沃泰克斯药物股份有限公司 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
CN105873915A (zh) 2016-08-17
US20190314392A1 (en) 2019-10-17
HUE048750T2 (hu) 2020-08-28
US20170065573A1 (en) 2017-03-09
TW201612169A (en) 2016-04-01
KR102331120B1 (ko) 2021-11-24
US20200297742A1 (en) 2020-09-24
KR20160101194A (ko) 2016-08-24
CA2936338A1 (en) 2015-07-16
PE20160898A1 (es) 2016-09-10
MX2016008715A (es) 2016-09-06
CL2016001744A1 (es) 2017-03-17
DK3092223T3 (da) 2020-03-16
EP3092223B1 (en) 2019-12-11
EP3677578A1 (en) 2020-07-08
US20180104265A1 (en) 2018-04-19
WO2015105929A1 (en) 2015-07-16
ES2771825T3 (es) 2020-07-07
LT3092223T (lt) 2020-02-25
RS59858B1 (sr) 2020-02-28
US20150191496A1 (en) 2015-07-09
US20160030456A1 (en) 2016-02-04
US20180250316A1 (en) 2018-09-06
SMT202000094T1 (it) 2020-03-13
JP6629738B2 (ja) 2020-01-15
SI3092223T1 (sl) 2020-02-28
US20170216325A1 (en) 2017-08-03
US20190125770A1 (en) 2019-05-02
AR102019A1 (es) 2017-02-01
JP2017503804A (ja) 2017-02-02
SG11201605620QA (en) 2016-08-30
EA201691133A1 (ru) 2017-05-31
CY1122768T1 (el) 2021-05-05
AU2015204785A1 (en) 2016-08-25
PL3092223T3 (pl) 2020-05-18
IL246596A0 (en) 2016-08-31
PT3092223T (pt) 2020-02-19
UY35946A (es) 2015-07-31
EP3092223A1 (en) 2016-11-16
US20170340653A1 (en) 2017-11-30
US9187506B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
EA202090553A1 (ru) Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
PH12018500259A1 (en) Muscarinic agonists
FR26C1014I1 (fr) Compositions pharmaceutiques contenant de l'insuline
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
GEAP201814248A (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
UY33376A (es) Sal de tipo hemifumarato
MX2016008968A (es) Compuestos organicos.
JP2017503804A5 (enExample)
HUE048750T2 (hu) (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
PH12017501668A1 (en) Bace1 inhibitors
BR112017020180A2 (pt) derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer
BR112016029604A2 (pt) ?sais farmaceuticamente aceitáveis, forma cristalina, padrão cristalino, composições farmacêuticas, sais de glucamina, utilização de um sal e de uma composição farmacêutica, método para o tratamento do câncer e composto para a utilização?
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease